Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
Aileron Therapeutics Announces Data From Cohort 1 Of Phase 1b Clinical Trial Of LTI-03 In Idiopathic Pulmonary Fibrosis
Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect
低剂量 LTI-03（2.5 mg BID）是一种 Caveolin-1 相关肽，降低了病理基底样细胞和成纤维细胞中多种促纤维化蛋白的表达，并增加了表明上皮健康的生物标志物的表达，这表明了潜在的治疗效果
Positive trend was observed in seven of eight IPF biomarkers evaluated
在评估的八种IPF生物标志物中，有七种观察到积极的趋势
Low-dose LTI-03 was well-tolerated, with no safety signal observed
低剂量 LTI-03 耐受性良好，未观察到安全信号
Data from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) is expected in the third quarter of 2024
评估高剂量 LTI-03（5 mg BID）的第 2 队列数据预计将于 2024 年第三季度公布
Company to host conference call on Wednesday, May 1st at 9:00 am ET
公司将于美国东部时间5月1日星期三上午9点举行电话会议
译文内容由第三方软件翻译。